Allergic Bronchopulmonary Aspergillosis

ABSTRACT

Allergic bronchopulmonary aspergillosis is an uncommon but serious respiratory condition characterized by chronic airway inflammation and airway damage resulting from persistent colonization by and sensitization to the fungus Aspergillus fumigatus. The immunopathogenesis of allergic bronchopulmonary aspergillosis involves several pathways. Aspergillus allergens stimulate an interleukin 5-mediated Th2 pathway responsible for the eosinophilic infiltrate, whereas aspergillus proteases promote epithelial activation and a potent chemokine response that induces neutrophilic airway inflammation. The resulting airway inflammation is intense, involves tissue damage and remodeling, and is linked with the severity of bronchiectasis. Treatment involves corticosteroids and antifungal therapy with oral azoles. Additional management seeks to monitor and control the other disease components of severe asthma, bronchiectasis, and disease exacerbations.

KEYWORDS

Allergic aspergillosis - asthma - induced sputum - eosinophil

REFERENCES

• 1 Wark P A, Gibson P G. Allergic bronchopulmonary aspergillosis: new concepts of pathogenesis and treatment.  Respirology. 2001;  6(1) 1-7
• 2 Patterson R, Greenberger G, Halwig M, Liotta J, Roberts M. Allergic bronchopulmonary aspergillosis.  Arch Intern Med. 1986;  146 916-918
• 3 Greenberger P, Miller T, Roberts M, Smith L. Allergic bronchopulmonary aspergillosis in patients with and without evidence of bronchiectasis.  Ann Allergy. 1993;  70 333-338
• 4 Laufer P, Fink J N, Burns W T, Singer G F, Kalbfleisch J H, Greenberger P A. Allergic bronchopulmonary aspergillosis in cystic fibrosis.  J Allergy Clin Immunol. 1984;  73 44-48
• 5 Chauhan B, Knutsen A P, Hutcheson P S, Slavin R G, Bellone C J. T-cell subsets, epitope mapping and HLA-restriction in patients with allergic bronchopulmonary aspergillosis.  J Clin Invest. 1996;  97 2324-2331
• 6 Chauhan B, Santiago L, Hutcheson P S et al.. Evidence for the involvement of two different MHC class II regions in susceptibility or protection in allergic bronchopulmonary aspergillosis.  J Allergy Clin Immunol. 2000;  106(4) 723-729
• 7 Brouard J, Knauer N, Boelle P Y et al.. Influence of interleukin-10 on Aspergillus fumigatus infection in patients with cystic fibrosis.  J Infect Dis. 2005;  191(11) 1988-1991
• 8 Saxena S, Madan T, Shah A, Muralidhar K, Sarma P U. Association of polymorphisms in the collagen region of SP-A2 with increased levels of total IgE antibodies and eosinophilia in patients with allergic bronchopulmonary aspergillosis.  J Allergy Clin Immunol. 2003;  111(5) 1001-1007
• 9 Eaton T E, Weiner Miller P, Garrett J E, Cutting G R. Cystic fibrosis transmembrane conductance regulator gene mutations: do they play a role in the aetiology of allergic bronchopulmonary aspergillosis?.  Clin Exp Allergy. 2002;  32(5) 756-761
• 10 Marchand E, Verellen-Dumoulin C, Mairesse M et al.. Frequency of cystic fibrosis transmembrane conductance regulator gene mutations and 5T allele in patients with allergic bronchopulmonary aspergillosis.  Chest. 2001;  119(3) 762-767
• 11 Mussaffi H, Greif J, Kornreich L et al.. Severe allergic bronchopulmonary aspergillosis in an infant with cystic fibrosis and her asthmatic father.  Pediatr Pulmonol. 2000;  29(2) 155-159
• 12 Miller P W, Hamosh A, Macek Jr M et al.. Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in allergic bronchopulmonary aspergillosis.  Am J Hum Genet. 1996;  59(1) 45-51
• 13 Noone P G, Knowles M R. “CFTR-opathies”: disease phenotypes associated with cystic fibrosis transmembrane regulator gene mutations.  Respir Res. 2001;  2(6) 328-332
• 14 Gibson P G, Wark P A, Simpson J L et al.. Induced sputum IL-8 gene expression, neutrophil influx and MMP-9 in allergic bronchopulmonary aspergillosis.  Eur Respir J. 2003;  21(4) 582-588
• 15 Hogaboam C M, Carpenter K J, Schuh J M, Buckland K F. Aspergillus and asthma-any link?.  Med Mycol. 2005;  43(suppl 1) S197-S202
• 16 Carpenter K J, Ewing J L, Schuh J M et al.. Therapeutic targeting of CCR1 attenuates established chronic fungal asthma in mice.  Br J Pharmacol. 2005;  145(8) 1160-1172
• 17 Madan T, Kaur S, Saxena S et al.. Role of collectins in innate immunity against aspergillosis.  Med Mycol. 2005;  43(suppl 1) S155-S163
• 18 Madan T, Reid K B, Singh M, Sarma P U, Kishore U. Susceptibility of mice genetically deficient in the surfactant protein (SP)-A or SP-D gene to pulmonary hypersensitivity induced by antigens and allergens of Aspergillus fumigatus .  J Immunol. 2005;  174 6943-6954
• 19 Kishor U, Madan T, Sarma P U, Singh M, Urban B C, Reid K B. Protective roles of pulmonary surfactant proteins, SP-A and SP-D, against lung allergy and infection caused by Aspergillus fumigatus .  Immunobiology. 2002;  205 610-618
• 20 Strong P, Reid K B, Clark H. Intranasal delivery of a truncated recombinant human SP-D is effective at down-regulating allergic hypersensitivity in mice sensitized to allergens of Aspergillus fumigatus .  Clin Exp Immunol. 2002;  130(1) 19-24
• 21 Madan T, Kishore U, Singh M et al.. Surfactant proteins A and D protect mice against pulmonary hypersensitivity induced by Aspergillus fumigatus antigens and allergens.  J Clin Invest. 2001;  107(4) 467-475
• 22 Madan T, Kishore U, Shah A et al.. Lung surfactant proteins A and D can inhibit specific IgE binding to the allergens of Aspergillus fumigatus and block allergen-induced histamine release from human basophils.  Clin Exp Immunol. 1997;  110(2) 241-249
• 23 Rathore V B, Johnson B, Fink J N, Kelly K J, Greenberger P A, Kurup V P. T cell proliferation and cytokine secretion to T cell epitopes of Asp f 2 in ABPA patients.  Clin Immunol. 2001;  100(2) 228-235
• 24 Skov M, Poulsen L K, Koch C. Increased antigen-specific Th-2 response in allergic bronchopulmonary aspergillosis (ABPA) in patients with cystic fibrosis.  Pediatr Pulmonol. 1999;  27(2) 74-79
• 25 Walker C, Bauer W, Braun R K et al.. Activated T cells and cytokines in bronchoalveolar lavages from patients with various lung diseases associated with eosinophilia.  Am J Respir Crit Care Med. 1994;  150(4) 1038-1048
• 26 Wark P AB, Simpson J, Saltos N, Slater S, Hensley M J, Gibson P G. Induced sputum eosinophils, neutrophils and bronchiectasis in allergic bronchopulmonary aspergillosis.  Eur Respir J. 2000;  16 1095-1101
• 27 Kauffman H F, Tomee J F, van de Riet M A, Timmerman A J, Borger P. Protease-dependent activation of epithelial cells by fungal allergens leads to morphologic changes and cytokine production.  J Allergy Clin Immunol. 2000;  105(6 Pt 1) 1185-1193
• 28 Borger P, Koeter G H, Timmerman J A, Vellenga E, Tomee J F, Kauffman H F. Proteases from Aspergillus fumigatus induce interleukin (IL)-6 and IL-8 production in airway epithelial cell lines by transcriptional mechanisms.  J Infect Dis. 1999;  180(4) 1267-1274
• 29 Reed C E, Kita H. The role of protease activation of inflammation in allergic respiratory diseases.  J Allergy Clin Immunol. 2004;  114(5) 997-1008
• 30 Nigam S, Ghosh P C, Sarma P U. A new glycoprotein allergen/antigen with the protease activity from Aspergillus fumigatus .  Int Arch Allergy Immunol. 2003;  132(2) 124-131
• 31 Patterson R, Greenberger P, Radin R, Roberts M. Allergic bronchopulmonary aspergillosis: staging as an aid to management.  Ann Intern Med. 1982;  96 286-291
• 32 Eaton T, Garrett J, Milne D, Frankel A, Wells A. Allergic bronchopulmonary aspergillosis in the asthma clinic. A prospective evaluation of CT in the diagnostic algorithm.  Chest. 2000;  118 66-72
• 33 Maurya V, Gugnani H C, Sarma P U, Madan T, Shah A. Sensitisation to aspergillus antigens and occurrence of allergic bronchopulmonary aspergillosis in patients with asthma.  Chest. 2005;  127 1252-1259
• 34 Khan A N, Jones C, Macdonald S. Bronchopulmonary aspergillosis: a review.  Curr Probl Diagn Radiol. 2003;  32 156-168
• 35 Flume P A, Strange C, Ye X, Ebeling M, Hulsey T, Clark L L. Pneumothorax in cystic fibrosis.  Chest. 2005;  128(2) 720-728
• 36 Ritz N, Ammann R A, Casaulta Aebischer C, Schoeni-Affolter F, Schoeni M H. Risk factors for allergic bronchopulmonary aspergillosis and sensitisation to Aspergillus fumigatus in patients with cystic fibrosis.  Eur J Pediatr. 2005;  164(9) 577-582
• 37 Rosenberg M, Patterson R, Roberts M, Wang J. The assessment of immunologic and clinical changes occurring during corticosteroid therapy for allergic bronchopulmonary aspergillosis.  Am J Med. 1978;  64 599-606
• 38 Safirstein B H, D'Souza M F, Simon G, Tai E, Pepys J. Five year follow-up of allergic bronchopulmonary aspergillosis.  Am Rev Respir Dis. 1973;  108 450-459
• 39 Wang J L, Patterson R, Roberts M, Ghory A C. The management of allergic bronchopulmonary aspergillosis.  Am Rev Respir Dis. 1979;  120 87-92
• 40 Hilton A M, Chatterjee S S. Bronchopulmonary Aspergillosis-treatment with beclomethasone dipropionate.  Postgrad Med J. 1975;  51(Suppl) 98-103
• 41 [No authors listed] . Inhaled beclomethasone dipropionate in allergic bronchopulmonary aspergillosis. Report to the Research Committee of the British Thoracic Association.  Br J Dis Chest. 1979;  73 349-356
• 42 Seaton A, Seaton R A, Wightman A J. Management of allergic bronchopulmonary aspergillosis without maintenance oral corticosteroids, a fifteen year followup.  QJM. 1994;  87 529-537
• 43 Wark P, Wilson A W, Gibson P G. Azoles for allergic bronchopulmonary aspergillosis.  Cochrane Database Syst Rev. 2000;  3 CD001108
• 44 Wark P, Hensley M J, Saltos N et al.. Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: a randomised controlled trial.  J Allergy Clin Immunol. 2003;  111 952-957
• 45 Stevens D A, Lee J Y, Schwartz H J, Jerome D, Catanzaro A. A randomised trial of itraconazole in allergic bronchopulmonary aspergillosis.  N Engl J Med. 2000;  342 756-762
• 46 Skov M, Main K M, Silleson I B, Muller J, Koch C, Lanng S. Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide.  Eur Respir J. 2002;  20 127-133